Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Share-based Compensation (2021 - 2025)

Kezar Life Sciences' Share-based Compensation history spans 5 years, with the latest figure at $2.1 million for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 32.94% year-over-year to $2.1 million; the TTM value through Sep 2025 reached $10.6 million, down 17.65%, while the annual FY2024 figure was $13.0 million, 28.26% down from the prior year.
  • Share-based Compensation for Q3 2025 was $2.1 million at Kezar Life Sciences, down from $2.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.6 million in Q3 2023 and bottomed at $1.9 million in Q4 2021.
  • The 5-year median for Share-based Compensation is $3.2 million (2024), against an average of $3.2 million.
  • The largest annual shift saw Share-based Compensation surged 105.99% in 2022 before it tumbled 51.99% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $1.9 million in 2021, then soared by 105.99% to $3.8 million in 2022, then fell by 15.64% to $3.2 million in 2023, then increased by 2.7% to $3.3 million in 2024, then plummeted by 35.41% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for KZR's Share-based Compensation are $2.1 million (Q3 2025), $2.4 million (Q2 2025), and $2.8 million (Q1 2025).